DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-8.37%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.26B
AUM Growth
+$5.26B
(-21%)
Cap. Flow
-$544M
Cap. Flow
% of AUM
-10.34%
Top 10 Holdings %
Top 10 Hldgs %
53.77%
Holding
466
New
22
Increased
24
Reduced
24
Closed
360
Top Buys
| 1 |
NewAmsterdam Pharma
NAMS
|
$87.7M |
| 2 |
Dynavax Technologies
DVAX
|
$66M |
| 3 |
Oscar Health
OSCR
|
$53.5M |
| 4 |
Legend Biotech
LEGN
|
$50.5M |
| 5 |
Indivior
INDV
|
$47.1M |
Top Sells
| 1 |
Nuvalent
NUVL
|
$157M |
| 2 |
Kura Oncology
KURA
|
$106M |
| 3 |
Catalyst Pharmaceutical
CPRX
|
$64.6M |
| 4 |
Neurocrine Biosciences
NBIX
|
$62.1M |
| 5 |
WAY
Waystar Holding Corp
WAY
|
$60.8M |
Sector Composition
| 1 | Healthcare | 88.36% |
| 2 | Industrials | 0.23% |
| 3 | Consumer Staples | 0.01% |
| 4 | Energy | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Nuvalent
NUVL
$5.52B
| $1.41B | 26.67% | 17,991,024 -2,000,000 | -10% | -$157M |
|
2
Viatris
VTRS
$12.3B
| $299M | 5.66% | 23,996,036 +3,013 | +0% | +$37.5K |
|
3
Centene
CNC
$14.3B
| $162M | 3.07% | 2,671,921 +19,732 | +0.7% | +$1.2M |
|
|
4
Oscar Health
OSCR
$4.31B
| $159M | 3.01% | 11,835,000 +3,983,325 | +51% | +$53.5M |
|
5
Revolution Medicines
RVMD
$7.1B
| $143M | 2.7% | 3,258,332 +345,640 | +12% | +$15.1M |
|
6
Merus
MRUS
$4.98B
| $125M | 2.37% | 2,972,787 -435,752 | -13% | -$18.3M |
|
|
WAY
7
Waystar Holding Corp
WAY
$6.6B
| $121M | 2.29% | 3,295,260 -1,656,744 | -33% | -$60.8M |
|
|
8
Neurocrine Biosciences
NBIX
$13.8B
| $118M | 2.23% | 862,000 -454,590 | -35% | -$62.1M |
|
9
ARS Pharmaceuticals
SPRY
$1.15B
| $111M | 2.1% | 10,514,657 -563,270 | -5% | -$5.94M |
|
|
10
NewAmsterdam Pharma
NAMS
$2.71B
| $111M | 2.1% | 4,314,340 +3,412,590 | +378% | +$87.7M |
|
|
11
Indivior
INDV
$3.03B
| $110M | 2.09% | 8,883,160 +3,790,518 | +74% | +$47.1M |
|
12
AdaptHealth
AHCO
$1.28B
| $92.5M | 1.75% | 9,711,410 | – | – |
|
13
Alignment Healthcare
ALHC
$3.24B
| $82.2M | 1.56% | 7,304,302 -3,550,683 | -33% | -$39.9M |
|
14
Larimar Therapeutics
LRMR
$310M
| $82.2M | 1.56% | 21,231,974 | – | – |
|
15
Brookdale Senior Living
BKD
$1.83B
| $78.5M | 1.49% | 15,612,264 | – | – |
|
16
IDEAYA Biosciences
IDYA
$2.15B
| $70.3M | 1.33% | 2,736,000 +142,000 | +5% | +$3.65M |
|
17
Embecta
EMBC
$847M
| $67.5M | 1.28% | 3,270,535 +540,192 | +20% | +$11.2M |
|
|
18
Dynavax Technologies
DVAX
$1.19B
| $66.3M | 1.26% | 5,193,823 +5,172,263 | +23,990% | +$66M |
|
|
19
Catalyst Pharmaceutical
CPRX
$2.52B
| $65.4M | 1.24% | 3,133,011 -3,096,623 | -50% | -$64.6M |
|
20
Owens & Minor
OMI
$378M
| $64.2M | 1.22% | 4,911,979 | – | – |
|
21
BioCryst Pharmaceuticals
BCRX
$1.74B
| $61.2M | 1.16% | 8,144,442 +8,638 | +0.1% | +$65K |
|
22
Baxter International
BAX
$12.7B
| $56.1M | 1.06% | 1,923,100 | – | – |
|
23
Edgewise Therapeutics
EWTX
$1.51B
| $55.5M | 1.05% | 2,078,509 +297,503 | +17% | +$7.94M |
|
|
24
Legend Biotech
LEGN
$6.41B
| $50.5M | 0.96% | +1,551,718 | New | +$50.5M |
|
25
Bio-Rad Laboratories Class A
BIO
$8.06B
| $49.8M | 0.94% | 151,644 +69 | +0% | +$22.7K |
|